Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT02325674

MEASuRE: Metreleptin Effectiveness And Safety Registry

MEASuRE: Metreleptin Effectiveness And Safety Registry — Recruiting • NCT02325674.

📅 16 Jul 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT02325674
Start
2016-10-11
Completion
2031-10-31
ClinicaliQ Trial Snapshot
  • MEASuRE: Metreleptin Effectiveness And Safety Registry — Recruiting • NCT02325674.
  • A registry tracking safety and effectiveness of metreleptin treatment in patients across the US and Europe.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA. Conditions: Generalised Lipodystrophy, Partial Lipodystrophy Interventions: Metreleptin Lead Sponsor: Chiesi Farmaceutici S.p.A. Planned Enrollment: 100 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn